Sentiment Change Report: Amphastar Pharmaceuticals (NASDAQ:AMPH) at 1.11

Positions for Amphastar Pharmaceuticals (NASDAQ:AMPH)

“Big money sentiment for Amphastar Pharmaceuticals (NASDAQ:AMPH) in 2018 Q2 decreased to 1.11, according to SEC.gov filings. That’s down -0.34, from 2018Q1’s 1.45. 50 hedge funds opened new and increased equity positions, while 45 decreased and sold holdings in Amphastar Pharmaceuticals so the sentiment dived. Funds own 19.80 million shares, down from 20.28 million shares in 2018Q1. Funds holding Amphastar Pharmaceuticals in top 10 changed to 0 from 0 for the same number . 11 Investors Sold All; 34 Reduced Holdings; 35 increased stakes while 15 hedge funds bought stakes.

Largest Amphastar Pharmaceuticals Investors

As of 2018 Q2 Cortina Asset Management Llc has 0.28% invested in Amphastar Pharmaceuticals. As of 2018 Q2, 235,775 shares of Amphastar Pharmaceuticals are owned by Argent Capital Management Llc. Furthermore, Federated Investors Inc Pa reported 1.28 million shares in Amphastar Pharmaceuticals equivalent to 0.06% of its fund portfolio. The New York-based fund Rothschild Asset Management Inc have invested about 0.05% of the institutional investor’s stock portfolio in Amphastar Pharmaceuticals. The New York-based fund Engineers Gate Manager Lp looks positive on Amphastar Pharmaceuticals, having 25,333 shares.

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable, inhalation, and intranasal products.The firm is valued at $1.01 billion. It operates in two divisions, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.Last it reported negative earnings. The companyÂ’s product portfolio comprises enoxaparin, a low molecular weight heparin that is used as an anticoagulant for prevention and treatment of deep vein thrombosis; naloxone for treating opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection for the dispersion and absorption of other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures.

AMPH is reaching $21.99 during the last trading session, after increased 1.24%.Amphastar Pharmaceuticals, Inc. is uptrending after having risen 17.25% since December 8, 2017. AMPH has 248,433 volume or 15.61% up from normal. The stock outperformed the S&P500 by 1.63%.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is expected to publish earnings on March, 11., Zacks reports. Analysts have expectation on stock’s EPS of $0.11. That’s up 10.00 % from last year’s $0.1 EPS. AMPH’s profit could be $5.07 million if the current EPS of $0.11 is accurate. After $0.12 EPS report previous quarter, Wall Street now forecasts -8.33 % negative EPS growth of Amphastar Pharmaceuticals, Inc..

Moreover, Blackrock has 0% invested in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Fisher Asset Ltd holds 0% or 130,468 shs in its capital. 39,942 are owned by Voya Inv Mngmt Limited Liability Corp. Aperio Grp Ltd Llc accumulated 17,815 shs. Dekabank Deutsche Girozentrale reported 19,200 shs or 0% of all its holdings. Barclays Plc stated it has 0% of its capital in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Pinnacle Fincl Partners Inc invested in 0% or 1,000 shs. New York State Common Retirement Fund invested in 0% or 42,720 shs. Invesco Limited stated it has 308,474 shs or 0% of all its holdings. California State Teachers Retirement Sys holds 0% of its capital in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) for 54,414 shs. Manufacturers Life The accumulated 27,913 shs or 0% of the stock. City Holdings Company accumulated 400 shs. Sei holds 0% or 67,934 shs. Financial Bank Of Montreal Can holds 0% or 2,191 shs in its capital. Louisiana State Employees Retirement System, a Louisiana-based fund reported 16,100 shs.

For more Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) news brought out briefly go to: Seekingalpha.com, Nasdaq.com, Streetinsider.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “Amphastar (AMPH) Q2 2018 Results – Earnings Call Transcript – Seeking Alpha” brought out on August 11, 2018, “TTEC Holdings, Inc. (TTEC) Ex-Dividend Date Scheduled for October 05, 2018 – Nasdaq” on October 04, 2018, “Amphastar Pharma (AMPH) Announces Reintroduction of Primatene MIST – StreetInsider.com” with a publish date: November 08, 2018, “Apple suppliers drop on Lumentum guide, iPhone target cuts – Seeking Alpha” and the last “Amphastar Pharmaceuticals’ (AMPH) Q1 2018 Results – Earnings Call Transcript – Seeking Alpha” with publication date: May 14, 2018.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.